Invest on your own
Build your own portfolio, stock by stock.
We do it for you
Professionally managed portfolios, built and rebalanced for you.
NEW
How we screen every stock
Our halal screening & purification process in 3 minutes
Screeners
Your portfolio
Calculators
TOOL
Check any stock in seconds
Search 11,000+ tickers and see the halal verdict instantly.
Our certifications
Independent proof that every stock and portfolio meets halal standards.
METHODOLOGY
How we screen every stock
Our 5-step halal methodology, in 90 seconds.
Get help
NEW
Halal investing 101
A beginner-friendly intro to investing the halal way.
Plans by product
COMPARE
Find your plan
See every feature side-by-side and pick what fits.
Investors
INVESTORS
Invest in Musaffa
We're building the financial house for 1.9B Muslims. See the deck.
SNDX Shariah Compliance
Screening Methodology: AAOIFI
NOT HALAL
Last Updated: June 19, 2026
Report Source: 2026 1st Quarter Report
Syndax Pharmaceuticals Inc. Stock Analysis SNDX
United States Health Care Small Cap Report: Syndax Pharmaceuticals, Inc. engages in the development of cancer therapies. The company is headquartered in New York City, New York and currently employs 298 full-time employees. The company went IPO on 2016-03-03. The company is focused on developing a pipeline of cancer therapies. Its product candidates include Revuforj and Niktimvo. The company is developing Revuforj, a potent, selective, small molecule inhibitor of the menin-MLL binding interaction for the treatment of KMT2A rearranged also known as mixed lineage leukemia rearranged, acute leukemias including acute lymphoblastic leukemia and acute myeloid leukemia (AML), and necleophosmin 1, also known as NPM1, mutant AML. The company is also exploring the use of Revuforj as a treatment in solid tumors, specifically its activity in metastatic colorectal cancer. The company is also developing Niktimvo, a monoclonal antibody that blocks the colony stimulating factor 1 receptor (CSF-1R) in chronic graft-versus-host disease (cGVHD), as well as idiopathic pulmonary fibrosis. Entinostat is its oral, small molecule product candidate that has direct effects on both cancer cells and immune regulatory cells.
Read More Syndax Pharmaceuticals Inc (SNDX) Chart
Key Statistics of Syndax Pharmaceuticals Inc (SNDX)
Key statistics in the stock market are essential financial indicators that measure a company's performance, valuation, profitability, and risk.
Today's Range
Today's Open
$19.32Volume
1.02MP/E Ratio (TTM)
-52 Week Range
Market Cap
1.75BAvg. Volume
1.92MDividend Yield
-Financial Metrics & Statements of Syndax Pharmaceuticals Inc (SNDX)
FAQ's for Syndax Pharmaceuticals Inc (SNDX)
- According to Musaffa’s Shariah screening methodology, Syndax Pharmaceuticals Inc (SNDX) is currently classified as NOT HALAL as of June 2026. The classification is based on an evaluation of the company’s business activities and financial ratios to determine whether it meets Islamic investment guidelines.
- A stock is Shariah-compliant if the company operates in permissible business activities and meets Islamic financial screening thresholds. Musaffa analyzes Syndax Pharmaceuticals Inc using these criteria to determine its compliance status.
- Muslim investors may consider investing in Syndax Pharmaceuticals Inc if it meets Shariah compliance standards. Investors typically review the company’s business activities, debt levels, and non-permissible income before making a decision.
- Musaffa determines the Shariah status of Syndax Pharmaceuticals Inc by analyzing whether the company’s core business operations are permissible and whether its financial ratios fall within accepted Islamic thresholds.
- The Shariah compliance status of Syndax Pharmaceuticals Inc may be updated periodically when new financial statements, earnings reports, or business activity information become available.
- Yes. A stock that is currently Shariah-compliant may become non-compliant if the company’s financial ratios exceed Shariah thresholds or its business activities change.
- You can check the latest Shariah compliance status of Syndax Pharmaceuticals Inc on Musaffa’s stock page, where screening results and key financial indicators are updated to help Muslim investors make informed decisions.